{"id":2546,"date":"2016-11-29T10:13:44","date_gmt":"2016-11-29T09:13:44","guid":{"rendered":"http:\/\/www.ematologialasapienza.it\/?page_id=2546"},"modified":"2023-11-14T18:26:03","modified_gmt":"2023-11-14T17:26:03","slug":"letteratura","status":"publish","type":"page","link":"https:\/\/www.ematologialasapienza.it\/?page_id=2546","title":{"rendered":"Letteratura"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container hundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-right:0px;--awb-padding-left:0px;--awb-margin-top:20px;--awb-margin-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"width:104% !important;max-width:104% !important;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:50px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-image-element \" style=\"text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);\"><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none fusion-animated\" data-animationType=\"fadeInDown\" data-animationDuration=\"1.0\" data-animationOffset=\"top-into-view\"><img decoding=\"async\" width=\"1950\" height=\"408\" title=\"compositletteraturaversione2\" src=\"https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2.jpg\" alt class=\"img-responsive wp-image-2672\" srcset=\"https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2-200x42.jpg 200w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2-400x84.jpg 400w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2-600x126.jpg 600w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2-800x167.jpg 800w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2-1200x251.jpg 1200w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/12\/compositLetteraturaVersione2.jpg 1950w\" sizes=\"(max-width: 640px) 100vw, 1200px\" \/><\/span><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:0px;--awb-margin-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_3_4 3_4 fusion-flex-column fusion-flex-align-self-flex-start fusion-column-no-min-height\" style=\"--awb-bg-size:cover;--awb-width-large:75%;--awb-margin-top-large:0px;--awb-spacing-right-large:3.84%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.56%;--awb-width-medium:75%;--awb-spacing-right-medium:3.84%;--awb-spacing-left-medium:2.56%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;width:100%;\"><\/div><div class=\"fusion-blog-shortcode fusion-blog-shortcode-1 fusion-blog-archive fusion-blog-layout-medium-alternate fusion-blog-pagination\" style=\"--awb-title-font-size:18px;--awb-timeline-title-font-size:18px;--awb-title-font-family:-apple-system, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, Oxygen-Sans, Ubuntu, Cantarell, &#039;Helvetica Neue&#039; ,sans-serif;--awb-title-font-style:normal;--awb-title-font-weight:400;\"><div class=\"fusion-posts-container fusion-posts-container-pagination fusion-blog-rollover\" data-pages=\"4\"><article id=\"blog-1-post-3421\" class=\"fusion-post-medium-alternate post-3421 post type-post status-publish format-standard hentry category-letteratura\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">7<\/span><span class=\"fusion-month-year\">03, 2018<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=3421\">Daratumumab nei pazienti con MM di nuova diagnosi: risultati ad interim dello studio ALCYONE<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=3\" title=\"Articoli scritti da editor contenuti\" rel=\"author\">editor contenuti<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>Nei pazienti anziani con mieloma multiplo (MM) di nuova diagnosi, non eleggibili per procedure trapiantologiche, i regimi pi\u00f9 largamente utilizzati prevedono l\u2019associazione di melphalan e prednisone con talidomide o bortezomib. Con questo tipo di trattamenti, sono stati registrati tassi di sopravvivenza libera da progressione (PFS) di 18-24 mesi e di [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=3421\" aria-label=\"More on Daratumumab nei pazienti con MM di nuova diagnosi: risultati ad interim dello studio ALCYONE\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-3033\" class=\"fusion-post-medium-alternate post-3033 post type-post status-publish format-standard hentry category-letteratura tag-blinatumomab tag-lal\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">22<\/span><span class=\"fusion-month-year\">03, 2017<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=3033\">Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=3\" title=\"Articoli scritti da editor contenuti\" rel=\"author\">editor contenuti<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2017-03-22T15:16:15+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><span class=\"meta-tags\">Tags: <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=blinatumomab\" rel=\"tag\">blinatumomab<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=lal\" rel=\"tag\">LAL<\/a><\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>E\u2019 stato recentemente pubblicato un importante studio di fase 3 che ha messo a confronto una chemioterapia di salvataggio (standard of care, SOC) versus blinatumomab (anticorpo bispecifico anti-CD19-CD3) per pazienti con leucemia acuta linfoblastica (LAL) della linea B CD19+ recidivati o refrattari. L\u2019abstract originale del lavoro \u00e8 qui di seguito [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=3033\" aria-label=\"More on Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-2563\" class=\"fusion-post-medium-alternate post-2563 post type-post status-publish format-standard hentry category-letteratura tag-emicizumab tag-emofilia-a tag-fattore-viii tag-inibitori\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">21<\/span><span class=\"fusion-month-year\">10, 2016<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2563\">Emofilia A: frequenza di inibitori e nuove terapie<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2016-11-30T08:59:39+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><span class=\"meta-tags\">Tags: <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=emicizumab\" rel=\"tag\">Emicizumab<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=emofilia-a\" rel=\"tag\">Emofilia A<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=fattore-viii\" rel=\"tag\">Fattore VIII<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=inibitori\" rel=\"tag\">Inibitori<\/a><\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>L\u2019emofilia A severa viene generalmente trattata con infusioni di fattore VIII, che tuttavia possono risultare pesanti per i pazienti e comportano lo sviluppo di inibitori specifici in circa il 30% dei casi. L\u2019ultimo numero del New England Journal of Medicine affronta questo problema presentando i risultati positivi ottenuti in pazienti [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=2563\" aria-label=\"More on Emofilia A: frequenza di inibitori e nuove terapie\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-2560\" class=\"fusion-post-medium-alternate post-2560 post type-post status-publish format-standard hentry category-letteratura tag-lal tag-rituximab\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">21<\/span><span class=\"fusion-month-year\">10, 2016<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2560\">LAL: miglior outcome con l\u2019aggiunta di rituximab<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2016-11-30T09:00:25+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><span class=\"meta-tags\">Tags: <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=lal\" rel=\"tag\">LAL<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=rituximab\" rel=\"tag\">Rituximab<\/a><\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>Il trattamento con l\u2019anticorpo monoclonale anti-CD20 rituximab ha migliorato significativamente la prognosi dei pazienti con linfoma non-Hodgkin. Lo studio randomizzato GRAALL-2005 (Maury S et al. NEJM, 2016;375:1044-53) dimostra ora che nei pazienti con leucemia acuta linfoblastica (LAL) B-cellulare CD20-positiva, l\u2019aggiunta di rituximab al protocollo chemioterapico \u00e8 in grado di migliorare [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=2560\" aria-label=\"More on LAL: miglior outcome con l\u2019aggiunta di rituximab\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-2573\" class=\"fusion-post-medium-alternate post-2573 post type-post status-publish format-standard hentry category-letteratura\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">26<\/span><span class=\"fusion-month-year\">05, 2016<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2573\">Mieloma multiplo: non tutte le trisomie sono uguali<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:02+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>Nei pazienti con Mieloma Multiplo (MM), la prognosi risulta largamente dipendente dalla presenza di anomalie cromosomiche, con la del(17p) e la t(4;14) che rappresentano le principali alterazioni associate con un peggiore outcome. Tuttavia, anche nell\u2019ambito di questi pazienti ad alto rischio, l\u2019andamento della malattia non \u00e8 uniforme e alcuni pazienti [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=2573\" aria-label=\"More on Mieloma multiplo: non tutte le trisomie sono uguali\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-2580\" class=\"fusion-post-medium-alternate post-2580 post type-post status-publish format-standard hentry category-letteratura tag-ibrutinib tag-llc\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">25<\/span><span class=\"fusion-month-year\">05, 2016<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2580\">Ibrutinib nella LLC: una medaglia a due facce<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:02+01:00<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=65\" rel=\"category\">Letteratura<\/a><span class=\"fusion-inline-sep\">|<\/span><span class=\"meta-tags\">Tags: <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=ibrutinib\" rel=\"tag\">Ibrutinib<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?tag=llc\" rel=\"tag\">LLC<\/a><\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p> Il trattamento con ibrutinib, inibitore orale della BTK, pu\u00f2 indurre una ricostituzione parziale dei linfociti B normali e dell\u2019immunit\u00e0 umorale nei pazienti con leucemia linfatica cronica (LLC). Questa osservazione proviene da uno studio (Sun C et al. Blood, 2015;126:2213-19) condotto su 86 pazienti con LLC non precedentemente trattata o [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=2580\" aria-label=\"More on Ibrutinib nella LLC: una medaglia a due facce\">Read More<\/a><\/div><\/div><\/article>\n<\/div><div class=\"pagination clearfix\"><span class=\"current\">1<\/span><a href=\"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fpages%2F2546&#038;paged=2\" class=\"inactive\">2<\/a><a class=\"pagination-next\" rel=\"next\" href=\"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fpages%2F2546&#038;paged=2\"><span class=\"page-text\">Prossimo<\/span><span class=\"page-next\"><\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_4 1_4 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:25%;--awb-margin-top-large:0px;--awb-spacing-right-large:7.68%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:3.84%;--awb-width-medium:25%;--awb-spacing-right-medium:7.68%;--awb-spacing-left-medium:3.84%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-widget-area awb-widget-area-element fusion-widget-area-1 fusion-content-widget-area\" style=\"--awb-title-size:12px;--awb-title-color:#333333;--awb-padding:0px 0px 0px 0px;\"><section id=\"nav_menu-3\" class=\"fusion-slidingbar-widget-column widget widget_nav_menu\"><div class=\"menu-menudxletteratura-container\"><ul id=\"menu-menudxletteratura\" class=\"menu\"><li id=\"menu-item-2578\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-2578\"><a title=\"Guarda tutti gli articoli pubblicati\" href=\"https:\/\/www.ematologialasapienza.it\/?page_id=2546\">Home Letteratura<\/a><\/li>\n<li id=\"menu-item-2568\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2568\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2563\">Emofilia A: frequenza di inibitori e nuove terapie<\/a><\/li>\n<li id=\"menu-item-2569\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2569\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2560\">LAL: miglior outcome con l\u2019aggiunta di rituximab<\/a><\/li>\n<li id=\"menu-item-2576\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2576\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2573\">Mieloma multiplo: non tutte le trisomie sono uguali<\/a><\/li>\n<li id=\"menu-item-2583\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2583\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2580\">Ibrutinib nella LLC: una medaglia a due facce<\/a><\/li>\n<li id=\"menu-item-2593\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2593\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2588\">Non utilit\u00e0 dello screening CT per tumori nel TEV<\/a><\/li>\n<li id=\"menu-item-2606\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2606\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2595\">Trattamento PET-guidato nel linfoma di Hodgkin<\/a><\/li>\n<li id=\"menu-item-2607\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2607\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2597\">ASH meeting 2014: novit\u00e0 sulle LAL<\/a><\/li>\n<li id=\"menu-item-2608\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2608\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2600\">Immunoterapia anti-PD-1 nel linfoma di Hodgkin<\/a><\/li>\n<li id=\"menu-item-2609\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2609\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2602\">Primi risultati del protocollo GIMEMA LAL 1509<\/a><\/li>\n<li id=\"menu-item-2610\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2610\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2604\">IFN tipo I ed efficacia delle antracicline<\/a><\/li>\n<li id=\"menu-item-2645\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2645\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2619\">Mantenimento con rituximab per le vasculiti ANCA+<\/a><\/li>\n<li id=\"menu-item-2646\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2646\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2622\">Remissioni durevoli di LAL con T cell chimeriche<\/a><\/li>\n<li id=\"menu-item-2647\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2647\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2624\">Potenziali target terapeutici nella LAL Ph-like<\/a><\/li>\n<li id=\"menu-item-2648\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2648\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2626\">Terapia del MM nell\u2019era dei \u201cnuovi farmaci\u201d<\/a><\/li>\n<li id=\"menu-item-2649\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2649\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2628\">Dalteparina pre-partum nella trombofilia<\/a><\/li>\n<li id=\"menu-item-2650\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2650\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2630\">AML: quale il ruolo delle alte dosi di Ara-C?<\/a><\/li>\n<li id=\"menu-item-2651\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2651\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2632\">Sirolimus post-HCT per la profilassi della GVHD<\/a><\/li>\n<li id=\"menu-item-2652\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2652\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2635\">Genetica di PTX3 e rischio di aspergillosi in HSCT<\/a><\/li>\n<li id=\"menu-item-2653\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2653\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2637\">Sottocloni con TP53 mutato e prognosi della LLC<\/a><\/li>\n<li id=\"menu-item-2654\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2654\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2639\">Profilassi anti-D prenatale: nuove line-guida BCSH<\/a><\/li>\n<li id=\"menu-item-2655\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2655\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2641\">Obinutuzumab-clorambucil nella LLC con comorbidit\u00e0<\/a><\/li>\n<li id=\"menu-item-2656\" class=\"menu-item menu-item-type-post_type menu-item-object-post menu-item-2656\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=2643\">Emofilia B: profilassi con rFIXFc a lunga emivita<\/a><\/li>\n<\/ul><\/div><div style=\"clear:both;\"><\/div><\/section><div class=\"fusion-additional-widget-content\"><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/2546"}],"collection":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2546"}],"version-history":[{"count":28,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/2546\/revisions"}],"predecessor-version":[{"id":12144,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/2546\/revisions\/12144"}],"wp:attachment":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}